Life Sciences

  • December 05, 2025

    Pharma Co. Says Ex-Staff Used Secrets To Compete

    Pharmaceutical supplier New Life Medicals (USA) Inc. told a North Carolina state court that a former warehouse manager, a freelance contractor and a business partner conspired to steal confidential information to form a competing venture only 10 miles away.

  • December 05, 2025

    Medline Accused In Chancery Of Withholding $10M Earnout

    A Florida-based holding company and its founder have sued medical supplier Medline in the Delaware Chancery Court, alleging it deliberately refused to make a $10 million payment tied to a 2023 acquisition, missed a hard deadline and is now acting in bad faith to avoid paying the key portion of the sale price.

  • December 05, 2025

    Mass Tort Firms Targeted Over Benicar MDL Fees In NJ Suits

    Robins Kaplan LLP and Pendley Baudin & Coffin were hit with proposed class actions in New Jersey state court from former clients in multidistrict litigation over the blood pressure medication Benicar alleging that the firms overcharged on their fees.

  • December 05, 2025

    CDC Panel Ends Recommendation Of Hepatitis B Shot At Birth

    A panel of federal vaccine advisers on Friday voted to lift a long-standing recommendation that all newborns be given vaccinations for hepatitis B.

  • December 04, 2025

    Wheeling & Appealing: The Latest Must-Know Appellate Action

    Is the False Claims Act constitutional? Will Mark Zuckerberg be deposed in high-profile privacy litigation? Did a major drugmaker's shenanigans cost investors nearly $7 billion? That's a small sample of the intriguing legal questions we're exploring in this preview of December's top appellate action.

  • December 04, 2025

    Class Cert. Denied In Splenda False Ad Suit

    A California federal judge on Wednesday declined to certify a class of consumers who claim that Splenda falsely advertised that its sweetener packets were "suitable for people with diabetes," partly because the lead plaintiff is prediabetic.

  • December 04, 2025

    11th Circ. Blocks Fla. City's Abortion Clinic Buffer Zone Law

    The Eleventh Circuit on Thursday ordered a preliminary injunction blocking a Clearwater, Florida, ordinance requiring a 5-foot buffer zone outside an abortion clinic, finding the city likely violated protesters' rights by burdening their ability to leaflet drivers.

  • December 04, 2025

    Squires Clarifies Points On Patent Eligibility Declarations

    U.S. Patent and Trademark Office Director John Squires is reminding applicants that they can file declarations explaining why their patents are eligible under Section 101 of the Patent Act and that examiners need to consider them when filed. 

  • December 04, 2025

    CDC Vaccine Committee Punts Hepatitis B Vote Again

    Federal vaccine advisers on Thursday put off a vote on changing guidelines for a long-used hepatitis B vaccine for infants, delaying again a decision expected to have wide-ranging ramifications for national childhood vaccine policy in the U.S.

  • December 04, 2025

    Fla. High Court Backs University Control Over Nonprofit

    The Florida Supreme Court on Thursday ruled that a university can control a research nonprofit's budget and approve its board members, saying a state law doesn't impair a memorandum of understanding between the two parties. 

  • December 04, 2025

    Geico Claims Cos. Ran $2.7M Medical Device Billing Scheme

    Two New York companies exploited the state's no-fault insurance laws by fraudulently billing Geico more than $2.7 million for unnecessary durable medical equipment for drivers involved in auto accidents who could receive no-fault coverage, the insurer told a New York federal court Thursday.

  • December 04, 2025

    Medical Device Co. Faces Investor Suit Over IV Pump Issues

    Medical device company Baxter International Inc. has been hit with a proposed investor class action accusing it of falsely claiming that it resolved issues associated with an IV pump before recalling the product this year.

  • December 04, 2025

    Pharma Cos. Denied Early Win In States' Price-Fixing Suit

    Twenty-six pharmaceutical companies failed to secure a quick win on overarching conspiracy claims in an antitrust case by the attorneys general of Connecticut and most other states, with a federal judge finding the "substantial bulk of evidence" points toward a broad industry scheme to fix 98 dermatology drug prices.

  • December 04, 2025

    Judge Nixes Hagens Berman's Recusal Bid After DOJ Referral

    Two days after referring powerhouse plaintiffs firm Hagens Berman to the U.S. Department of Justice for alleged misconduct, a Pennsylvania federal judge on Thursday dismissed the firm's request that he recuse himself from the long-running product liability suit, calling the firm's arguments "absurd."

  • December 04, 2025

    Vivimed To Pay $1.9M To End Losartan Economic Loss Claims

    Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood pressure medication, according to a Wednesday filing.

  • December 03, 2025

    USPTO Gets Earful On Plan To Restrict Patent Reviews

    The U.S. Patent and Trademark Office's proposed new rules to limit America Invents Act patent reviews have generated scores of forceful comments, with supporters saying the proposal will curb redundant challenges and opponents arguing it would bar legitimate reviews and exceed the office's power.

  • December 03, 2025

    Pharmacies Want Opioid Mistrial As Deliberations Stretch On

    The nation's three major pharmacy chains asked a Florida state judge Wednesday to declare a mistrial following 11 days of deliberations in a $1.5 billion case by hospitals over opioid dispensing, claiming jurors seem unaware that they are allowed to report a deadlock.

  • December 03, 2025

    Pharma Co. Exec Faces $125K SEC Judgment In Fraud Case

    A New York federal judge on Wednesday approved a $125,000 civil penalty against the former chief science officer of BioZone Pharmaceuticals Inc. for his alleged involvement in a purported pump-and-dump scheme involving the company's stock.

  • December 03, 2025

    NuVasive Urges Del. Justices To Revive Officer Conflict Suit

    A Delaware vice chancellor applied the wrong standards in tossing a suit alleging a former officer of spine surgery tech venture NuVasive Inc. ran an insider scheme to lure surgeons to a competitor while planning his own jump, an attorney for NuVasive told a Delaware Supreme Court panel on Wednesday.

  • December 03, 2025

    Kevin O'Leary, Company Execs Fight Patent Forgery Suit

    A livestock technology company and several of its executives and investors, including Kevin O'Leary of "Shark Tank," have asked a Colorado federal judge to throw out the lawsuit against them by the company's founder, who claims the defendants stole her company and intellectual property.

  • December 03, 2025

    'Dr. P.' Gets 2.5 Years For Selling Ketamine To Matthew Perry

    A California federal judge sentenced a former physician who supplied Matthew Perry with ketamine before the "Friends" actor's overdose death to 2 years and 6 months in prison Wednesday, following the doctor's July guilty plea to four counts of illegally distributing the drug.

  • December 03, 2025

    AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing

    AT&T has joined the bevy of litigants suing a swath of pharmaceutical companies over alleged generic drug price-fixing, claiming it shelled out billions of dollars for medication reimbursements to the drugmakers as part of its employee health plans when it could have spent far less if the drugs weren't subject to anticompetitive pricing.

  • December 03, 2025

    Novartis, Swiss Marketer Want Out Of Trade Secrets Suit

    A Swiss marketing company and its founder have joined pharmaceutical giant Novartis in asking a Manhattan federal judge to release them from a hedge fund's suit accusing the founder of brokering business meetings with Novartis in a scheme to steal its strategy, claiming the suit is merely an attempt to punish Novartis for placing money with a competitor.

  • December 03, 2025

    Fed. Circ. Backs Axed Claims In Heart Rate Monitor Patent

    The Federal Circuit on Wednesday upheld a Utah federal court's decision that claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy were invalid under the U.S. Supreme Court's Alice test.

  • December 03, 2025

    Judge To OK $16.5M 23andMe Insurer Buyback Deal In Ch. 11

    A Missouri bankruptcy judge Wednesday agreed to approve a $16.5 million settlement between genetic testing company 23andMe and its insurers, in which the carriers proposed to buy back the unused portion of their cyber coverage.

Expert Analysis

  • USPTO's AI Tool Redefines Design Patent Landscape

    Author Photo

    The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.

  • Class Actions At The Circuit Courts: August Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses key takeaways from federal appellate decisions involving topics including antitrust, immigration, consumer fraud, birthright citizenship under the Fourteenth Amendment, and product defects.

  • Series

    Hiking Makes Me A Better Lawyer

    Author Photo

    On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.

  • What US-India Trade Deal Will Mean For Indian Pharma

    Author Photo

    Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.

  • Opinion

    Time For Full Disclosure Of Third-Party Funding In MDLs

    Author Photo

    It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow.

  • Series

    Law School's Missed Lessons: Negotiation Skills

    Author Photo

    I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.

  • Conflicting Developments In Homelessness Legal Landscape

    Author Photo

    Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

  • Location Data And Online Tracking Trends To Watch

    Author Photo

    Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.

  • A Simple Way Courts Can Help Attys Avoid AI Hallucinations

    Author Photo

    As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors.

  • DOJ Consumer Branch's End Leaves FDA Litigation Questions

    Author Photo

    With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, companies must carefully monitor how responsibility is reallocated for civil and criminal enforcement cases related to products regulated by the U.S. Food and Drug Administration, say attorneys at Foley & Lardner.

  • The Evolving Legal Landscape For THC-Infused Beverages

    Author Photo

    A recent Eighth Circuit ruling, holding that states may restrict the sale of intoxicating hemp-derived products without violating federal law, combined with ongoing regulatory uncertainty at both the federal and state levels, could alter the trajectory of the THC-infused beverage market, say attorneys at Pashman Stein.

  • Series

    Creating Botanical Art Makes Me A Better Lawyer

    Author Photo

    Pressing and framing plants that I grow has shown me that pursuing an endeavor that brings you joy can lead to surprising benefits for a legal career, including mental clarity, perspective and even a bit of humility, says Douglas Selph at Morris Manning.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.